Breast cancer

Genetic Technologies Reports Q1 FY22 Results

Woman, Genetypes, Colorectal cancer, Polygene, IBX, Ovarian cancer, Epidemiology, Marketing, National, ASX, COVID-19, Colditz, NATA, Health, Acquisition, GLOBE, Research, DTC, National public health institutes, Completeness, Company, Direct, Norwegian Institute of Public Health, Institute, Coronary artery disease, European, IBX Group, Risk, Public health, Genetic causes of type 2 diabetes, Awareness, PLOS, Biobank, Population, GTG, Breast cancer, Single-nucleotide polymorphism, Cancer, Certification, NASDAQ, CIT, Applied Genetic Technologies Corporation, Board, Washington University in St. Louis, Roy Taylor (scientist), Type 2 diabetes, Prostate cancer, UK Biobank, Agriculture, Pharmaceutical industry, Fine chemical, Video game, Medical device, Birth control
Monday, October 25, 2021 - 1:30pm

The Multi-Test is a Predictive Panel Risk Test to cover six common cancers which account for ~70% of annual morbidities.

Key Points: 
  • The Multi-Test is a Predictive Panel Risk Test to cover six common cancers which account for ~70% of annual morbidities.
  • Phase one launch to include Breast Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Coronary Artery Disease and Type-2 Diabetes.
  • Commenting on the quarter, CEO Simon Morriss stated: This past quarter demonstrates the forward trajectory and momentum Genetic Technologies has established.
  • Authorised for release by the Board of Genetic Technologies Limited.

Rain Therapeutics Hosting Research and Development (R&D) Day

KOL, Breast cancer, Cancer, Memorial Sloan Kettering Cancer Center, Neoplasm, Brown University, Histology, MD Anderson Cancer Center, LPS, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, RAIN, Liposarcoma, MDM2, Center, Lists of people executed in the United States, RAD52, Hematology-Oncology and Stem Cell Transplantation Research Center, University, Research and development, Clinical trial, Webcast, Roswell Park Comprehensive Cancer Center, DD, R, Oncology, Therapy, National Cancer Institute, Q&A, GLOBE, Division, Doctor of Philosophy, Nasdaq, Department, Genetics, Management, Medical imaging, Vaccine, Pharmaceutical industry
Monday, October 25, 2021 - 1:00pm

NEWARK, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced that it will host a virtual Research and Development (R&D) day on Tuesday, November 9, 2021 from 11:00 am to 2:00 pm Eastern Time.

Key Points: 
  • NEWARK, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced that it will host a virtual Research and Development (R&D) day on Tuesday, November 9, 2021 from 11:00 am to 2:00 pm Eastern Time.
  • We are excited to share a detailed update on our plans for milademetan in our inaugural R&D day, saidAvanish Vellanki, co-founder and chief executive officer of Rain.
  • We look forward to hosting several KOLs in oncology to discuss the potential opportunity in various MDM2-dependent patient populations.
  • The webcast will also be available under the Events and Presentations section of the Rain website.

Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients

Safety, Program, Neoplasm, Twitter, U.S. Securities and Exchange Commission, Dalhousie University, Radiation, Survival rate, RWE, NCI, North American Association of Central Cancer Registries, Cyberknife, Erasmus, Incidence, Association, Survival, BEIR, Security (finance), Private Securities Litigation Reform Act, Intelligence, SLC Agrícola, Literature, Pooled analysis, Risk, Panacea Medical Technologies, Real, Synchrony, International Institute for Population Sciences, SLC, Breast cancer, SEC, ABPI, FABS, Surveillance, Erasmus MC, SRP, Population, Frontiers, Technology, LinkedIn, Annual report, Lung, Database, Patient, NASDAQ, YouTube, SEER, Time, Forward-looking statement, Mortality, Medical imaging, Pharmaceutical industry
Monday, October 25, 2021 - 12:30pm

SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ --Accuray Incorporated(NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife robotic radiotherapy platform.

Key Points: 
  • SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ --Accuray Incorporated(NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife robotic radiotherapy platform.
  • The addition of radiotherapy can extend survival that may be offset by the development of a secondary cancer like lung tumors many years following treatment.
  • This study reinforces the unparalleled accuracy of a 4-like robotic CyberKnife platform and shows its tremendous potential as a treatment for early-stage breast cancer," said Suzanne Winter, president at Accuray.
  • Breast cancer stage distribution and number of new cases were obtained from the North American Association of Central Cancer Registries (NAACCR).

WORKPRO® Tools Renews Commitment And Increases Pledge To National Breast Cancer Foundation, Inc.®

Breast cancer, DIY, Disease, Patient navigators, Organization, Partnership, Charity Navigator, National Breast Cancer Foundation (United States), Gold, Platinum, National Breast Cancer Foundation, NASCAR, Hangzhou GreatStar Industrial, CEO, Multimedia, Amazon, Woman, Education, Birth control
Sunday, October 24, 2021 - 4:10am

WORKPRO is featuring an assortment of essential hand tools, power tools and accessories that are appropriately colored in pink.

Key Points: 
  • WORKPRO is featuring an assortment of essential hand tools, power tools and accessories that are appropriately colored in pink.
  • As part of the new commitment, WORKPRO Tools is stepping up its co-marketing efforts with NBCF.
  • Recognized as one of the leading breast cancer organizations in the world, National Breast Cancer Foundation (NBCF) is Helping Women Now by providing early detection, education and support services to those affected by breast cancer.
  • Developed by Hangzhou GreatStar Industrial Co., Ltd., the largest hand tool manufacturer in Asia, WORKPRO Tools delivers a diverse variety of hand tools, power tools and storage solutions.

Advanced Radiation Therapy, LLC and Apollo Healthcare Announce Strategic Partnership

Apollo, Breast cancer, Technology, Hospital, Cancer, NIBB, Health care, ART, Partnership, Patient, Insurance, Adoption, Prior authorization, LLC, Medicare, ASTRO, GLOBE, Society, Physician, Medical imaging, Health insurance
Friday, October 22, 2021 - 10:15pm

TYNGSBORO, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Advanced Radiation Therapy, LLC (ART) and Apollo Healthcare have today announced a strategic partnership aimed at easing the challenge radiation oncology clinics have in pre-authorizing patients for insurance coverage for innovative radiation cancer therapies.

Key Points: 
  • TYNGSBORO, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Advanced Radiation Therapy, LLC (ART) and Apollo Healthcare have today announced a strategic partnership aimed at easing the challenge radiation oncology clinics have in pre-authorizing patients for insurance coverage for innovative radiation cancer therapies.
  • Apollo Healthcare is ready to serve as an additional resource to clinics utilizing ARTs products and technology.
  • ART will be showcasing this new partnership at the upcoming American Society of Therapeutic Radiation Oncologists (ASTRO) annual meeting in Chicago, Illinois from October 24-27, 2021.
  • Advanced Radiation Therapy, headquartered outside of Boston, MA, is an innovator inprecision radiation therapy for breast cancer.

Context Therapeutics® Announces Closing of Initial Public Offering, Including Full Exercise of Underwriter’s Over-allotment Option

Breast cancer, Cancer, Immunotherapy, State Street, Trial master file, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, ThinkEquity, Telephone, SEC, Exercise, Forward-looking statement, Company, Disclosure, Intention, Nasdaq, Prospectus, Therapy, GLOBE, Sale, Form
Friday, October 22, 2021 - 9:05pm

ThinkEquity acted as sole book-running manager for the offering.

Key Points: 
  • ThinkEquity acted as sole book-running manager for the offering.
  • 333-256572) relating to the shares was filed with the Securities and Exchange Commission (SEC) and became effective on October 19, 2021.
  • Context Therapeutics Inc. (Nasdaq: CNTX) is a womens oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers.
  • ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven womens cancers.

Illinois Jury Awards $72 Million Verdict in Environmental Exposure Suit

Breast cancer, Cancer, Marmon Group, Furan, Cueto, Kidney cancer, Multimedia, Courage, Male, Marmon, Female, Bladder cancer, Dioxin, Tobacco
Friday, October 22, 2021 - 5:42pm

An Illinois jury awarded $72 million to 12 plaintiffs in a personal injury case against Cerro Flow Products LLC.

Key Points: 
  • An Illinois jury awarded $72 million to 12 plaintiffs in a personal injury case against Cerro Flow Products LLC.
  • Cerro owned and operated a secondary copper smelting plant in Sauget, IL for more than 50 years.
  • All 12 plaintiffs lived in East St. Louis, Illinois in the neighborhoods that surrounded the Cerro plant and incurred more than four decades of exposure to the chemical compounds.
  • Another 10,000 residents who have not been diagnosed to date have also filed suit regarding the toxic exposure.

Shop Pink Kyocera Kitchen Tools to Raise Funds for Breast Cancer Research in October

Woman, Breast cancer, The Wall Street Journal, Research, SAN, Kyocera, Forbes, World, Breast, Breast Cancer Research Foundation, Organic, Kyocera Communications, Man, Metal, Ceramic, Philosophy, Birth control
Friday, October 22, 2021 - 3:30pm

SAN DIEGO, Oct. 22, 2021 /PRNewswire-PRWeb/ -- Kyocera , a leader in ceramic cutlery since 1984, continues over a decade of support for breast cancer research with its special edition pink ceramic kitchen tools line.

Key Points: 
  • SAN DIEGO, Oct. 22, 2021 /PRNewswire-PRWeb/ -- Kyocera , a leader in ceramic cutlery since 1984, continues over a decade of support for breast cancer research with its special edition pink ceramic kitchen tools line.
  • In honor of breast cancer awareness month in October, the pink line is 10% off with the promo code 21KYBCA and Kyocera will donate 10% of sales proceeds to the Breast Cancer Research Foundation.
  • According to breastcancer.org, about 1 in 8 women in the U.S. will develop invasive breast cancer in their lifetime, as will 1 in 833 men.
  • With more than 78,000 employees worldwide, Kyocera Group offices also support breast cancer charities in Japan, South Korea, and China.

Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor T

Event, Lung, Head, Melanoma, Cancer, Breast cancer, Research, CD4, ACHL, CD8, Patient, ESGCT, NASDAQ, Large-cell lung carcinoma, MAP, TNF, Cell, Congress, TIL, Protein, United Kingdom, Company, Intention, National Association Medical Staff Services, Gene, GLOBE, European Society of Gene and Cell Therapy, Neck, DNA, Medical imaging, Vaccine
Friday, October 22, 2021 - 12:30pm

cNeT target clonal neoantigens, which are unique proteins expressed on every cancer cell within a patient but not on healthy tissue.

Key Points: 
  • cNeT target clonal neoantigens, which are unique proteins expressed on every cancer cell within a patient but not on healthy tissue.
  • MAPshowcases the analytical strength of the Achilles platform, delivers vital translational science insights, and highlights our organizational and supply chain expertise.
  • Additionally, analysis of CD4+ and CD8+ cells in cNeT products shows favorable cell phenotypes consistent with high cell fitness and reduced cell exhaustion.
  • Additional data for renal and bladder tumor samples were still in process at the time of submission.

Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM‘21

Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Newton, Head, Neoplasm, Twitter, EANM, Olivia, GBM, Nausea, Graft-versus-host disease, Chemokine, United Kingdom, COVID-19, Rheumatoid arthritis, Granulocyte-macrophage colony-stimulating factor, A3, Nuclear medicine, Judgement, Research, Association, Colorectal cancer, Risk, GM-CSF, Lung cancer, Prostate cancer, Toxicity, Department, Goal, Hypertension, European Journal of Nuclear Medicine and Molecular Imaging, Medication, Marketing, School, SEC, Central European, Fever, Principal, CEO, Scott Halstead, Nasdaq, Chills, Glioblastoma, Melanoma, Breast cancer, Cancer, LinkedIn, Knowledge, La Trobe University, Patient, Molecular imaging, Forward-looking statement, Development, Intention, European Association of Urology, GM, Pharmaceutical industry, Vaccine, Medical imaging, Risk management
Friday, October 22, 2021 - 12:00pm

EANM is the largest organization dedicated to nuclear medicine in Europe and represents more than 9,000 specialists from 41 different countries.

Key Points: 
  • EANM is the largest organization dedicated to nuclear medicine in Europe and represents more than 9,000 specialists from 41 different countries.
  • Our preclinical studies with antibody-drug conjugate forms of ifabotuzumab have shown promising results.
  • The Olivia Newton-John Cancer Research Institute plans to conduct a Phase 1b dose-escalation and imaging study in non-CNS solid tumors that is scheduled to begin in early 2022.
  • We look forward to supporting our valued partners in Australia as they advance research of ifabotuzumab into solid tumors.